An interventional study of Antioxidant-rich supplementation Element and Antioxidant-rich supplementation Optimal in Overweight , Obesity and Antioxidant Status, sponsored by National University of Singapore. Recruiting at 2 sites in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.
Among the 83 studies in Obesity with a site in Singapore, this one is the 31st largest by planned enrollment of the 68 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 17 of the 24 other live ones, and was the 77th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 21–70 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 83 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 70 across the 68 interventional studies, 200 across the 15 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.
National University of Singapore has 7 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07225556Eli Lilly and CompanyA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy | 2026-12 |
| NCT07444073National University of SingaporeAssessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | 2026-12-31 |
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Obesity with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of antioxidant-rich supplementation on skin carotenoid status, antioxidant status, and cardiometabolic health in overweight and obese individuals. The study may provide additional scientific evidence to support the further refinement of current dietary and nutritional recommendations.
This study will be a single-blind, randomized, parallel-group trial, and all participants will complete a 12-week study period. A total of 66 participants will be recruited and randomly assigned to continue their habitual diet with or without antioxidant-rich supplementation. This study aims to investigate whether antioxidant-rich supplementation will influence body composition, skin carotenoid status, antioxidant status, and cardiometabolic health. The study will comprise 1 screening visit and 4 test visits.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 83 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maintained habitual diet without receving the intervention.
Consume the LifePak (Elements) every day for 12 weeks.
Dietary Supplement: Antioxidant-rich supplementation Element
Consume the LifePak (Optimal) every day for 12 weeks.
Dietary Supplement: Antioxidant-rich supplementation Optimal
Maintained habitual diet with additionally taking LifePak Element for 12 weeks
Maintaining habitual diet with additionally taking LifePak Optimal for 12 weeks
Change in Skin Carotenoid Score Measured by Prysm iO™ from Baseline to Week 12
Skin carotenoid status will be assessed using the Prysm iO™ device. The device scans the participant's fingertip and provides a skin carotenoid score, also referred to as the Prysm Score. Results will be reported as the numerical Prysm Score. Higher scores indicate higher skin carotenoid levels.
Time frame: Week 0, 4, 8, 12
Mean Change from Baseline in Blood Carotenoid Concentration
Blood carotenoid concentration will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood carotenoid concentration at Week 12. Higher concentrations indicate higher circulating carotenoid status.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Total Antioxidant Capacity in Blood Samples
Total antioxidant capacity will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in total antioxidant capacity at each post-baseline time point.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Fasting Blood Lipid and Lipoprotein Concentrations
Fasting blood lipid and lipoprotein concentrations will be assessed using blood samples collected from participants after an overnight fast. The lipid and lipoprotein profile may include total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Results will be reported as the mean change from baseline in each lipid and lipoprotein parameter at Week 12.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Fasting Blood Glucose Concentration
Fasting blood glucose concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood glucose concentration at Week 12.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Fasting Blood Insulin Concentration
Fasting blood insulin concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood insulin concentration at Week 12.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Blood Biomarkers of Oxidative Stress: Malondialdehyde and 8-Isoprostane
Oxidative stress will be assessed using blood samples collected from participants. Blood biomarkers of oxidative stress will include malondialdehyde and 8-isoprostane. Results will be reported as the mean change from baseline in malondialdehyde concentration and 8-isoprostane concentration at Week 12. Higher concentrations indicate higher levels of oxidative stress.
Time frame: Week 0 and Week 12
Mean Change from Baseline in Skin Autofluorescence Measured by AGE Reader mu Connect
Skin advanced glycation end product accumulation will be assessed non-invasively using the AGE Reader mu Connect. The device measures skin tissue autofluorescence on the inside of the participant's dominant lower forearm. Results will be reported as the mean change from baseline in AGE Reader measurement result, expressed in arbitrary units. Higher values indicate higher skin advanced glycation end product accumulation.
Time frame: Week 0, 4, 8, 12
Mean Change from Baseline in Blood Advanced Glycation End Product Level
Blood advanced glycation end product level will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood advanced glycation end product level at Week 12.
Time frame: Week 0 and Week 12
Mean change from baseline in anthropometric and body composition parameters
Anthropometric and body composition parameters will be assessed using standard measurements and InBody body composition analysis. Parameters may include body weight, waist circumference, body fat percentage, fat mass, fat-free mass, skeletal muscle mass and body mass index. Results will be reported as the mean change from baseline at each post-baseline time point.
Time frame: Week 0, 4, 8, 12
Mean Change from Baseline in Blood Clock Gene-Related Markers
Clock gene-related markers will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in selected clock gene-related markers at Week 12. This outcome is exploratory and will be used to explore potential biological changes associated with the intervention.
Time frame: Week 0 and Week 12
Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University of Singapore →